{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:01:38Z","timestamp":1790488898756,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Allergen immunotherapy (AIT) is a well-established treatment with demonstrated efficacy and safety. However, variability in study outcomes remains a challenge, driven by differences in patient characteristics, study designs, and treatment durations. Moreover, disparities in allergen composition and quality of AIT products across manufacturers contribute to significant heterogeneity, complicating the interpretation of efficacy and safety data. This meta-analysis focuses on assessing the efficacy and safety of a single manufacturer\u2019s liquid sublingual immunotherapy (SLIT) for allergic rhinoconjunctivitis (ARC). By narrowing the scope to one specific product, this study seeks to reduce variability linked to product differences, aligning with recommendations from the World Allergy Organization to improve the reliability of meta-analytic findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized controlled trials (RCTs) on index of reactivity (IR) SLIT liquid formulations of various allergens were identified through comprehensive searches in electronic databases (MEDLINE, ISI Web of Science, the Cochrane Library, and ClinicalTrial.gov) up to December 2024, complemented by manual searches. Data on populations, treatments, and outcomes were extracted. Efficacy was evaluated by calculating the standardized mean difference (SMD) for symptoms and medication use. Subgroup analyses were performed by age, allergen type and sensitization status. Asthma comorbidity, dose and duration of SLIT were evaluated using meta-regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 25 RCTs (1,830 patients) provided data on symptom scores (SS), and 19 RCTs (1,555 patients) reported on medication scores (MS). Analysis revealed that IR-SLIT-liquid was significantly more effective than placebo in reducing both SS (SMD: \u22120.30; 95% CI: \u22120.41 to \u22120.18;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.0001) and MS (SMD: \u22120.51; 95% CI: \u22120.72 to \u22120.29;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.0001). Efficacy outcomes were consistent regardless of factors such as age, allergen type (grass, house dust mites, trees, weeds), sensitization status, asthma presence, or cumulative dose, while longer treatment durations were associated with improved efficacy. No significant adverse events were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This meta-analysis underscores the clinical effectiveness and safety of IR-SLIT-liquid, confirming its role as a reliable etiologic treatment for patients with ARC, for all allergens and age groups. The effect size is comparable to other immunotherapy options. The low rates of adverse events and treatment withdrawals highlight favorable tolerability and high level of patient adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/inplasy.com\/wp-content\/uploads\/2025\/01\/INPLASY-Protocol-7305.pdf<\/jats:ext-link>\n                      , INPLASY 202510049\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2025.1597003","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T01:29:28Z","timestamp":1749086968000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of index of reactivity-liquid sublingual immunotherapy in allergic rhinoconjunctivitis: a systematic review and meta-analysis of randomized studies"],"prefix":"10.3389","volume":"6","author":[{"given":"Danilo","family":"Di Bona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Biase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Serviddio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiane","family":"Cognet-Sic\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Scurati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/j.1398-9995.2010.02439.x","article-title":"Development and implementation of guidelines in allergic rhinitis\u2014an ARIA-GA2LEN paper","volume":"65","author":"Bousquet","year":"2010","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/jamainternmed.2015.2840","article-title":"Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis","volume":"175","author":"Di Bona","year":"2015","journal-title":"JAMA Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2012.08.012","article-title":"Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison","volume":"130","author":"Di Bona","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD002893","DOI":"10.1002\/14651858.CD002893.pub2","article-title":"Sublingual immunotherapy for allergic rhinitis","author":"Radulovic","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"CD001936","DOI":"10.1002\/14651858.CD001936.pub2","article-title":"Allergen injection immunotherapy for seasonal allergic rhinitis","author":"Calderon","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jaci.2013.02.013","article-title":"Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison","volume":"131","author":"Dretzke","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.37349\/eaa.2023.00012","article-title":"Impact of the standardization unit\u2019s definition on the in vitro biological potency of allergen extracts","volume":"1","author":"Batard","year":"2023","journal-title":"Explor Asthma Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.37349\/eaa.2025.100968","article-title":"Influence of the definition of the standardization unit on the in vitro potency of cat allergen extracts","volume":"3","author":"Batard","year":"2025","journal-title":"Explor Asthma Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40413-015-0078-8","article-title":"Allergen immunotherapy on the way to product-based evaluation\u2014a WAO statement","volume":"8","author":"Bachert","year":"2015","journal-title":"World Allergy Organ J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B11","volume-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations","author":"Sch\u00fcnemann","year":"2013"},{"key":"B12","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","author":"Higgins","year":"2022"},{"key":"B13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/all.13317","article-title":"EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis","volume":"73","author":"Roberts","year":"2018","journal-title":"Allergy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B15","article-title":"Chapter 5: Collecting data","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5","author":"Li","year":"2024"},{"key":"B16","article-title":"Chapter 8: Assessing risk of bias in a randomized trial","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.2","author":"Higgins","year":"2021"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/sim.1221","article-title":"A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials","volume":"21","author":"Baujat","year":"2002","journal-title":"Stat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"key":"B20","article-title":"McMaster University and Evidence Prime (2021)","year":""},{"key":"B21","article-title":"Metafor: Meta-Analysis Package for R. R package Version 2010","author":"Viechtbauer","year":""},{"key":"B22","year":""},{"key":"B23","article-title":"Version 2.0. Internovi, Cesena, Italy","year":""},{"key":"B24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1398-9995.1994.tb02273.x","article-title":"A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract","volume":"49","author":"Sabbah","year":"1994","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1398-9995.1998.tb04086.x","article-title":"Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis","volume":"53","author":"Clavel","year":"1998","journal-title":"Allergy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1111\/j.1398-9995.2009.02194.x","article-title":"Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study","volume":"64","author":"Ott","year":"2009","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1365-2222.2008.03159.x","article-title":"Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen","volume":"39","author":"Stelmach","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"B28","first-page":"139","article-title":"Immunoterapia podj\u0119zykowa jest skuteczna i bezpieczna u dzieci","volume":"16","author":"Ka\u0142uzi\u0144ska-Parzyszek","year":"2011","journal-title":"Alergia Astma Immunologia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1398-9995.2011.02758.x","article-title":"Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children","volume":"67","author":"Stelmach","year":"2012","journal-title":"Allergy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2500\/ajra.2014.28.4091","article-title":"Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis","volume":"28","author":"Bozek","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.anai.2014.03.019","article-title":"Objective approach for fending off the sublingual immunotherapy placebo effect in subjects with pollenosis: double-blinded, placebo-controlled trial","volume":"113","author":"Kralimarkova","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1517\/14740338.2012.626765","article-title":"Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study","volume":"11","author":"Sieber","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"B33","first-page":"175","article-title":"Efficacy of sublingual swallow immunotherapy in children with rye grass pollen allergic rhinitis: a double-blind placebo-controlled study","volume":"11","author":"Ahmadiafshar","year":"2012","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S1081-1206(10)62726-3","article-title":"Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma\u2013a placebo controlled study","volume":"82","author":"Mungan","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1034\/j.1398-9995.2000.00413.x","article-title":"House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study","volume":"55","author":"Guez","year":"2000","journal-title":"Allergy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ppul.1088","article-title":"Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study","volume":"32","author":"Bah\u00e7eciler","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"B37","first-page":"105","article-title":"Changes in serum specific IgG4 and IgG4\/IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: a multicenter, randomized, placebo-controlled trial","volume":"26","author":"Tseng","year":"2008","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1164\/rccm.200905-0686OC","article-title":"House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells","volume":"180","author":"O'Hehir","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.rmed.2013.06.021","article-title":"Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial","volume":"107","author":"Aydogan","year":"2013","journal-title":"Respir Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/cea.12039","article-title":"House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis","volume":"43","author":"Bozek","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"B41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.anai.2014.12.015","article-title":"Clinical and cytokine responses to house dust mite sublingual immunotherapy","volume":"114","author":"Potter","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1365-2222.2005.00102.x","article-title":"Effects of high-dose sublingual immunotherapy on quality of life in patients with cypress-induced rhinitis: a placebo-controlled study","volume":"6","author":"Di Rienzo","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"B43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1046\/j.1398-9995.2003.00387.x","article-title":"Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study","volume":"59","author":"Khinchi","year":"2004","journal-title":"Allergy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000097026","article-title":"Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study","volume":"142","author":"Vervloet","year":"2007","journal-title":"Int Arch Allergy Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1185\/03007990903431886","article-title":"Effectiveness of high dose sublingual immunotherapy to induce a stepdown of seasonal asthma: a pilot study","volume":"26","author":"Voltolini","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"B46","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1398-9995.1998.tb03952.x","article-title":"Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization","volume":"53","author":"Vourdas","year":"1998","journal-title":"Allergy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-7022-4-7","article-title":"Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study","volume":"4","author":"Worm","year":"2014","journal-title":"Clin Transl Allergy"},{"key":"B48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1081-1206(10)61408-1","article-title":"Canadian Trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis","volume":"93","author":"Bowen","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s0091-6749(99)70388-x","article-title":"Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis","volume":"104","author":"La Rosa","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/all.13201","article-title":"Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis","volume":"72","author":"Dhami","year":"2017","journal-title":"Allergy"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/all.12188","article-title":"House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma","volume":"69","author":"Wang","year":"2014","journal-title":"Allergy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"971155","DOI":"10.3389\/falgy.2022.971155","article-title":"The MaDo real-life study of dose adjustment of allergen immunotherapy liquid formulations in an indication of respiratory allergic disease: reasons, practices, and outcomes","volume":"3","author":"Th\u00e9tis-Souli\u00e9","year":"2022","journal-title":"Front Allergy"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100915","DOI":"10.1016\/j.lanepe.2024.100915","article-title":"Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)","volume":"41","author":"Demoly","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"B54","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jaci.2022.01.007","article-title":"Allergen immunotherapy for long-term tolerance and prevention","volume":"149","author":"Penagos","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/039463201202500122","article-title":"Medical management and sublingual immunotherapy practices in patients with house dust mite-induced respiratory allergy: a retrospective, observational study","volume":"25","author":"Trebuchon","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1007\/s12325-020-01345-7","article-title":"Relevant patient benefit of sublingual immunotherapy with birch pollen allergen extract in allergic rhinitis: an open, prospective, non- interventional study","volume":"37","author":"Blome","year":"2020","journal-title":"Adv Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/all.13598","article-title":"Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma","volume":"74","author":"Wahn","year":"2019","journal-title":"Allergy"}],"updated-by":[{"DOI":"10.3389\/falgy.2025.1652198","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000}}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1597003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T17:03:37Z","timestamp":1753463017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1597003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":57,"alternative-id":["10.3389\/falgy.2025.1597003"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1597003","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"article-number":"1597003"}}